Skip to Content
Merck
  • Transferrin iron starvation therapy for lethal bacterial and fungal infections.

Transferrin iron starvation therapy for lethal bacterial and fungal infections.

The Journal of infectious diseases (2014-01-22)
Lin Lin, Paul Pantapalangkoor, Brandon Tan, Kevin W Bruhn, Tiffany Ho, Travis Nielsen, Eric P Skaar, Yaofang Zhang, Ruipeng Bai, Amy Wang, Terence M Doherty, Brad Spellberg
ABSTRACT

New strategies to treat antibiotic-resistant infections are urgently needed. We serendipitously discovered that stem cell conditioned media possessed broad antimicrobial properties. Biochemical, functional, and genetic assays confirmed that the antimicrobial effect was mediated by supra-physiological concentrations of transferrin. Human transferrin inhibited growth of gram-positive (Staphylococcus aureus), gram-negative (Acinetobacter baumannii), and fungal (Candida albicans) pathogens by sequestering iron and disrupting membrane potential. Serial passage in subtherapeutic transferrin concentrations resulted in no emergence of resistance. Infected mice treated with intravenous human transferrin had improved survival and reduced microbial burden. Finally, adjunctive transferrin reduced the emergence of rifampin-resistant mutants of S. aureus in infected mice treated with rifampin. Transferrin is a promising, novel antimicrobial agent that merits clinical investigation. These results provide proof of principle that bacterial infections can be treated in vivo by attacking host targets (ie, trace metal availability) rather than microbial targets.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Enterobactin, from Escherichia coli, ≥98% (HPLC)